Cell death and cancer: Replacement of apoptotic genes and inactivation of death suppressor genes in therapy

Gene Therapy

Volumn 5, Issue 6, 1998, Pages 728-739

  Favrot, M ^a   Coll, J L ^a   Louis, N ^b   Negoescu, A ^a  

^a INSTITUT ALBERT BONNIOT   (France)

^b CENTRE LÉON BÉRARD   (France)

Author keywords

Apoptosis; Cancer; Gene therapy

Indexed keywords

PROTEIN BAX; PROTEIN P53;

APOPTOSIS; CELL DEATH; CELL KILLING; GENE THERAPY; GENE TRANSFER; PRIORITY JOURNAL; REVIEW; SUPPRESSOR GENE;

EID: 0031828248     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300661     Document Type: Review

References (217)

1. Green DR, Bissonnette RP, Cotter TG. Apoptosis and cancer. In: DeVita VT, Hellman S, Rosenberg SA (eds). Important Advances in Oncology. JB Lippincott: Philadelphia, 1994, pp 37-52.
2. Kerr JFR, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-2026.
3. Yang E, Korsmeyer S. Molecular thanatopsis: a discourse on the bcl2 family and cell death. Blood 1996; 88: 386-401.
4. Ko JK, Prives C. P53: puzzle and paradigm. Genes Dev 1996; 10: 1054-1072.
5. Brambilla E et al. Apoptosis-related factors P53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Palhol 1996; 149: 1941-1952.
6. Perego P et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996; 56: 556-562.
7. Krajewski S et al. Reduced expression of proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55: 4471-1487.
8. Kerr JFR, VVyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-257.
9. VVyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. Int Rev Cytol 1980; 68: 251-305.
10. Steel GG. Cell loss as a factor in the growth rate of human tumors. Eiir / Cancer 1967; 3: 381-387.
11. Kerr KM, Lamb D. Actual growth rate and tumour cell proliferation in human pulmonary neoplasms. Br J Cancer 1984; 50: 343-349.
12. VVyllie AH. The biology of cell death in tumors. Anticancer Res 1985; 5: 131-136.
13. Kerr JFR, Searle J. A suggested explanation for the paradoxically slow growth rate of basal-cell carcinomas that contain numerous mitotic figures. J Pathol 1972; 107: 41-44.
14. Schatten WE. An experimental study of necrosis in tumors. Dinar Res 1962; 22: 286-290.
15. Sarraf CE, Bowen ID. Proportions of mitotic and apoptotic cells in a range of untreated experimental tumors. Cell Tiss Kind 1988; 21: 45-49.
16. Staunton MJ, Gaffney EF. Tumor type is a determinant of susceptibility to apoptosis. Am ] Clin Pnthol 1995; 103: 300-307.
17. Bursch W et al. Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci of rats. Cnrdnogenesis 1990; 11: 847-853.
18. Arends MJ, McGregor AH, Wyllie AH. Apoptosis is inversely related to necrosis and determines net growth in tumors bearing constitutively expressed myc, ras and HPV oncogenes. Am J Pathol 1994; 144: 1045-1057.
19. Raff MC. Social control on cell survival and cell death. Nature 1992; 356: 397-399.
20. de Pinho RA, Schreiber-Agus N, Alt FW. Myc family oncogenes in the development of normal and neoplastic cells. Adv Cancer Res 1991; 57: 1-16.
21. Fotedar R, Diedrich L, Fotedar A. Apoptosis and the cell cycle. Prog Cell Cycle Res 1996; 2: 147-163.
22. Evan GI et al. Induction of apoptosis in fibroblasts by c-Myc protein. Cell 1992; 69: 119-128.
23. Dou QP, An B, Will PL. Induction of a rb phosphatase activity by anticancer drugs accompanies p53-independent Gl arrest and apoptosis. Proc Natl Acad Sri USA 1995; 92: 9019-9023.
24. Haas-Kogan DA et al. Inhibition of apoptosis by the rb gene product. EMBO J 1995; 14: 461-472.
25. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997; 89: 1845-1853.
26. Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell Prolif 1991; 24: 203-214.
27. McDonnell TJ, Meyn RE, Robertson LE. Implications of apoptotic cell death regulation in cancer therapy. Semin Cancer Biol 1995; 6: 53-60.
28. Tenniswood MP et al. Active cell death in hormone-dependent tissues. Cancer Metast Rev 1992; 11: 197-220.
29. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. CdJ 1994; 78: 539-542.
30. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997; 89: 21-39.
31. Sikora K. Gene therapy for cancer. Eur J Cancer 1991; 27: 1069-1070.
32. Weinberg RA. Tumor suppressor genes. Science 1991; 254: 1138-1146.
33. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell 1993; 74: 609-619.
34. Tsujimoto Y et al. The t(14;18) chromosome translocations involved in B cell neoplasms result from mistakes in VDJ joining. Science 1985; 229: 1390-1393.
35. Hockenbery DM. Bcl2 in cancer, development and apoptosis. J Cell Sci 1994; 18 (Suppl.): 51-55.
36. Sedlak TW el al. Multiple Bcl2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 1995; 92: 7834-7838.
37. Kernohan NM, Cox LS. Regulation of apoptosis by Bcl2 and its related proteins: immunocytochemical challenges and therapeutic implications. J Pathol 1996; 179: 1-3.
38. Saegusa M, Kamata Y, Isono M, Okayasu I. Bcl2 expression is correlated with a low apoptotic index and associated with progesterone receptor immunoreactivity in endomelrial carcinomas. J Pathol 1996; 180: 275-282.
39. Koshida Y, Saegusa M, Okayasu I. Apoptosis, cell proliferation and expression of Bcl2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study. Br ] Cancer 1997; 75: 367-373.
40. Rampino N et al. Somatic frameshift mutations in the bax gene in colon cancers of the microsatellite mutator phenotype. Science 1997; 275: 967-969.
41. Boise LH et al. BclX, a bcl2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
42. Minn AJ, Boise LH, Thompson CB. BclX S antagonizes the protective effects of BclX L. J Biol Chem 1996; 271: 6306-6312.
43. Martin SJ, Green DR. Protease activation during apoptosis: death by a thousand cuts? Cell 1995; 82: 349-352.
44. AInemri ES el al. Human ICEJCED3 protease nomenclature. Cell 1996; 87: 171.
45. VVyllie AH. Death gets a brake. Nature 1994; 369: 272-273.
46. Chinnaiyan AM et al. Molecular ordering of the cell death pathway: Bcl2 and BclX L function upstream of the CED3-like apoptotic proteases. J Biol Chcm 1996; 271: 4573-4576.
47. Simonian PL, Grillot DAM, Merino R, Nunez G. Bax can antagonize BclX L during etoposide and cisplatin-induced cell death independently of its heterodimerization with BclX L. J Biol Chem 1996; 271: 22764-22772.
48. Simonian PL et al. Bax homodimerization is not required for Bax to accelerate chemotherapy-induced cell death. J Biol Chem 1996; 271: 32073-32077.
49. Xiang J, Chao DT, Korsmeyer SJ. Bax-induced cell death may not require ICE enzyme-like proteases. Proc Natl Acad Sci USA 1996; 93: 14559-14563.
50. McCarthy NJ, Whyte MKB, Gilbert CS, Evan GE. Inhibition of CED3JICE proteases does not prevent cell death induced by oncogenes, DNA damage or the Bcl2 homologue Bak. J Cell Biol 1997; 136: 215-227.
51. Kinzler KW, Vogelstein B. Life (and death) in a malignant tumor. Nature 1996; 379: 19-20.
52. Clurman B, Groudine M. Killer in search of a motive? Nature 1997; 389: 122-123.
53. Lane DP. P53, guardian of the genome. Nature 1992; 358:15-16.
54. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53 dependent negative response element in the bcl2 gene. Cancer Res 1994; 54: 3131-3135.
55. Miyashita T et al. Tumor suppressor p53 is a regulator of bcl2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-1805.
56. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
57. Yin C, Knudson CM, Korsmeyer SJ, van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997; 385: 637-640.
58. Lowe SVV, Ruley HE, Jacks T, Housman DE. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-967.
59. Lowe SVV et al. P53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-810.
60. Clarke AR et al. Thymocyte apoptosis induced by P53-dependent and independent pathways. Nature 1993; 362: 849-852.
61. Clarke AR et al. P53 dependence of early apoptotic and proliferative responses \vithin the mouse intestinal epithelium following g-irradiation. Oncogene 1994; 9: 1767-1773.
62. Datta R et al. Overexpression of BclXL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ 1995; 6: 363-370.
63. Lowe SVV et al. P53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-848.
64. Momand J et al. The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245.
65. Oliner JD et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-63.
66. Kondo S et al. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 1995; 10: 2001-2006.
67. Haupt Y, Barak Y, Oren M. Cell type-specific inhibition of p53mediated apoptosis by mdm2. EMBO J 1996; 15: 1596-1606.
68. Strasser A et al. S. Bcl2 and FasJApol regulate distinct pathways to lymphocyte apoptosis. EMBO J 1995; 14: 6136-6147.
69. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365.
70. O'Reilly LA, Huang DCS, Strasser A. The cell death inhibitor BcI2 and its homologues influence control of cell cycle entry. EMBO ] 1996; 15: 6979-6990.
71. Borner C. Diminished cell proliferation associated with the death-protective activity of Bcl2. J Biol Clicm 1996; 271: 12695-12698.
72. Bacchetti S, Graham FL. Inhibition of cell proliferation by an adenovirus vector expressing the human wild-type p53 protein. Int J Oncol 1993; 3: 781-788.
73. Baker SJ el al. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249: 912-915.
74. Casey G el al. Growth suppression of human breast cancer by the introduction of a wild-type p53 gene. Oncogene 1991; 6: 1791-1797.
75. Chen Y et al. Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate. Oncogene 1991; 6: 1799-1805.
76. Cirielli C el al. Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in two. In t J Cancer 1995; 63: 673-679.
77. Eastham JA et al. In vivo gene therapy \vith p53 or p21 for prostate cancer. Cancer Res 1995; 55: 5151-5155.
78. Eicher SA et al. Evaluation of topical gene therapy for head and neck squamous cell carcinoma in an organotypic model. Clin Cancer Res 1996; 2: 1659-1664.
79. Hamada K et al. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res 1996; 56: 3047-3054.
80. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Nail Cancer lust 1996; 88: 1442-1455.
81. Isaacs VVB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 1991; 51: 4716-4720.
82. Kimura M et al. Inability to induce the alteration of tumorigenicity and chemosensitivity of p53-null human pancreatic carcinoma cells after the transduction of wild-type p53 gene. Anticancer Res 1997; 17: 879-883.
83. Liu TJ et al. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994; 54: 3662-3667.
84. Liu TJ et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 1995; 55: 3117-3122.
85. Matozaki T et al. P53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells. Cancer Res 1992; 52: 4335-4341.
86. Ramqvist T et al. Wild-type p53 induces apoptosis in a Burkitt lymphoma line that carries mutant p53. Oncogene 1993; 8: 1495-1500.
87. Santoso JT ct al. Adenovirus based p53 gene therapy in ovarian cancer. Gynecol Oncol 1995; 59: 171-178.
88. Shaw P et al. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992; 89: 4495-4499.
89. Vikhanskaya F, Erba E, d'Incalci M, Broggini M. Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res 1994; 22: 10121017.
90. Wang J, Bucana CD, Roth JA, Zhang VVVV. Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther 1995; 2:9-17.
91. Wang NP, To H, Lee WH, Lee EYHP. Tumor suppressor activity of rb and p53 genes in human breast carcinoma cells. Oncogene 1993; 8: 279-288.
92. Yang B, Stambrook PJ, Markowitz SD. Wild-type p53 demonstrates functional dominance in a human colon carcinoma cell line in which it induces reversible growth arrest. Clin Cancer Res 1996; 2: 1639-1647.
93. Yang C, Cirielli C, Capogrossi MC, Passaniti A. Adenovirus-mediated \vild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 1995; 55: 4210-4213.
94. Yonish-Rouach E et al. P53-mediated cell death: relationship to cell cycle control. Mol Cell Biol 1993; 13: 1415-1423.
95. Zhang YVW et al High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994; 1: 5-13.
96. Qazilbash MH et al. Cancer gene therapy using a novel adenoassociated virus vector expressing human wild-type p53. Gene Therapy 1997; 4: 675-682.
97. Ookawa K, Tsuchida S, Adachi JI, Yokota J. Differentiation induced by rb expression and apoptosis induced by p53 expression in an osteosarcoma cell line. Oncogens 1997; 14: 1389-1396.
98. Sala A et al. Apoptotic response to oncogenic stimuli: co-operative and antagonistic interactions between c myb and the growth suppressor p53. Cancer Res 1996; 56: 1991-1996.
99. Wang Y et al. Reconstitution of wild-type p53 expression triggers apoptosis in a p53-negative v-myc retrovirus-induced T cell lymphoma line. Cell Growth Diff 1993; 4: 467-473.
100. Wang Y et al. Wild-type p53-triggered apoptosis is inhibited by bcl2 in a v-myc-induced T cell lymphoma line. Oncogeiie 1993; 8: 3427-3431.
101. Mercer WE et al. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 1990; 87: 6166-6170.
102. Badie B et al. Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. Nenrol Res 1995; 17: 209-216.
103. Köck H et al. Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. Int J Cancer 1996; 67: 808-815.
104. Spitz FR et al. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res 1996; 16: 3415-3422.
105. Saito Y, Ogawa K. Wild-type p53 and c-myc co-operation in generating apoptosis of a rat hepatocellular carcinoma cell line (FAA-HTC1). Oncogene 1995; 11: 1013-1018.
106. Cai DW et al. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum Gene Ther 1993; 4: 617-624.
107. Fujiwara T et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus mediated-transfer of the wild-type p53 gene. Cancer Res 1994; 54: 2287-2291.
108. Katayose D, Wersto R, Cowan KH, Seth P. Effects of a recombinant adenovirus expressing WaflJCipl on cell growth, cell cycle and apoptosis. Cell Growth Diff 1995; 6: 1207-1212.
109. Fujiwara T et al. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993; 53: 4129-4133.
110. Adachi JI et al. Induction of apoptosis but not Gl arrest by expression of the wild-type p53 gene in small cell lung carcinoma. Cell Growth Diff 1996; 7: 879-886.
111. dayman GL et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995; 55: 1-6.
112. dayman GL et al. Gene therapy for head and neck cancer: comparing the tumor suppressor gene p53 and a cell cycle regulator waflJcipl(p21). Arch Otolaryngol Head Neck Snrg 1996; 122: 489-493.
113. Fujiwara T et al. Therapeutic effect of a retroviral wild-type p53 vector in an orthotopic lung cancer model. J Natl Cancer lust 1994; 86: 1458-1462.
114. Lesson-Wood LA et al. Systemic gene therapy with p53 reduces growth and métastases of a malignant human breast cancer in nude mice. Hum Gene Ther 1995; 6: 395-405.
115. Radinski R et al. Terminal differentiation and apoptosis in experimental lung métastases of human osteogenic sarcoma cells by wild-type p53. Oncogene 1994; 9: 1877-1883.
116. Yang B, Eshelman JR, Berger NA, Markowitz SD. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 1996; 2: 1649-1657.
117. Gomez-Manzano C cl al. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 1996; 56: 694-699.
118. Chen X, Ko LJ, Jayaraman L, Prives C. P53 levels, functional domains and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 1996; 10: 2438-2451.
119. Ronen D et al. Induction of HL60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels. Cell Growth Diff 1996; 7: 21-30.
120. Wang XW et ni. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev 1996; 10: 1219-1232.
121. Lassus P, Frelin M, Piette J, Hibner U. Anti-apoptotic activity of low levels of wild-type p53. EMBO J 1996; 15: 4566-4573.
122. Selivanova G et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nature Mcd 1997; 3: 632-638.
123. Xu M et al. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. Hum Gene Ther 1997; 8: 177-185.
124. Hamel W, Magnelli L, Chiarugi VP, Israel MA. HSV-TKJ ganciclovir-mediated apoptotic death by bystander cells. Cancer Res 1996; 56: 2696-2702.
125. Samejima Y, Meruelo D. Bystander killing induces apoptosis and is inhibited by forskolin. Gene Therapy 1995; 2: 50-58.
126. Freeman SM et al. The bystander effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
127. Whartenby KA et al. The biology of cancer gene therapy. Lab Invest 1995; 72: 131-145.
128. Mesnil M et al. Bystander killing of cancer cells by HSV-TK is mediated by connexins. Proc Natl Acad Sci USA 1996; 93: 1831-1835.
129. Chen L, Waxman DJ. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P450 gene transfer: development of a combined chemotherapyJcancer gene therapy strategy. Cancer Res 1995; 55: 581-589.
130. Wu JK et al. Bystander tumoricidal effect in the treatment of experimental brain tumors. Nenrosnrgery 1994; 35: 1094-1103.
131. Negoescu A et al. Contribution of apoptosis to the phenotypic changes of adrenocortical cells in primary culture. Mol Cell Endocrinol 1995; 110: 175-184.
132. Barba D, Hardin J, Sadelain M, Gage FH. Development of antitumor immunity following HSV-TK-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 1994; 91: 43484352.
133. Vile RG et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSV-TK gene involves an immune component. Cancer Res 1994; 54: 6228-6234.
134. Dilber MS et al. Suicide gene therapy for plasma cell tumors. Blood 1996; 88: 2192-2200.
135. Dilber MS, Smith CIE. Suicide genes and bystander killing: local and distant effects. Gene Therapy 1997; 4: 273-274.
136. Wilson KM et al. HSV-TK gene therapy in head and neck squamous cell carcinoma: enhancement by the local and distant bystander effect. Arch Otolaryngol Head Neck Snrg 1996; 122: 746-749.
137. Waldman T et al. Cell-cycle arrest versus cell death in cancer therapy. Nature Med 1997; 3: 1034-1036.
138. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
139. Liebermann DA, Hoffman B, Steinman RA. Molecular controls of growth arrest and apoptosis: p53 dependent and independent pathways. Oncogene 1995; 11: 199-210.
140. Gaelics C, Helmberg A, Karin M. P53-dependent apoptosis in the absence of transcriptional activation of P53-target genes. Nature 1994; 370: 220-223.
141. Pietenpol JA, Vogelstein B. No room at the p53 inn. Nature 1993; 365: 17-18.
142. Owen-Schaub LB et al. Wild-type human p53 and a temperature-sensitive mutant induce FasJAPOl expression. Mol Cell Biol 1995; 15: 3032-3040.
143. Tamura T et al. Induction of Fas-mediated apoptosis in p53transfected human colon carcinoma cells. Oncogene 1995; 11: 1939-1946.
144. van Meir EG et al. Release of an inhibitor of angiogenesis upon induction of \vild-type p53 expression in glioblastoma cells. Nature Genet 1994; 8: 171-176.
145. Dameron KM et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondinl. Science 1994; 265: 15821584.
146. Kieser A et al. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994; 9: 963-969.
147. Roth JA. Clinical protocol: modification of tumor suppressor gene expression in non-small cell lung cancer (NSCLC) with a retroviral vector expressing wild-type (normal) p53. Hum Gene Ther 1996; 7: 861-874.
148. Roth JA et al. Retrovirus mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Mcd 1996; 2: 985-991.
149. Chase GA et al. Department of Health and Human Services National Institutes of Health Recombinant DNA Advisory Committee minutes of meeting: 4-5 December 1995. Hum Gene Ther 1997; 8: 1137-1186.
150. O'Connor PM et al. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 1993; 53: 4776-4780.
151. Gjerset RA et al. Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Molec Carcinog 1995; 14: 275-285.
152. Spitz FR et al. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 1996; 2: 1665-1671.
153. Xu GVV et al. Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wild-type p53 gene. Hepatology 1996; 24: 1264-1268.
154. Nguyen DM et al. Disruption of p53 function sensitizes breast cancer MCF7 cells to cisplatin and pentoxifylline. Cancer Res 1995; 55: 1649-1654.
155. Wahl AF et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2JM arrest and apoptosis. Nature Med 1996; 2: 72-79.
156. Fan S et al. Disruption of p53 function sensitizes breast cancer MCF7 cells to cisplatin and pentoxifylline. Cancer Res 1995; 55: 1649-1654.
157. Goldsmith ME et al. Wild-type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J Biol Chem 1995; 270: 1894-1898.
158. Roth JA. Clinical protocol: modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wild-type p53 and cisplatin. Hum Gene Ther 1996; 7:1013-1030.
159. Bayever E et al. Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences. Lenk Lymphoma 1994; 12: 223-231.
160. Bishop MR et al. Phase I trial of and antisense oligonucleotide OL(1) p53 in hématologie malignancies. J Clin Oncol 1996; 14: 1320-1326.
161. El-Deiry WS et al. WaflJcipl is induced in p53-mediated Gl arrest and apoptosis. Cancer Res 1994; 54: 1169-1174.
162. Harper JW et al. The p21 cdk-interacting protein cipl is a potent inhibitor of cyclin-dependent kinases. Cell 1993; 75: 805-816.
163. Xiong Y et al. P21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-704.
164. Hooper ML. The role of p53 and rbl genes in cancer, development and apoptosis. J Cell Sci 1994; 18: 13-17.
165. White E. P53, guardian of Rb. Nature 1994; 371: 21-22.
166. Jung JM et al. Inhibition of human glioblastoma cell growth by VVaflJCipl can be attenuated by mutant P53. Cell Growth Diff 1995; 6: 909-913.
167. Skotzko M et al. Retroviral vector-mediated gene transfer of antisense cyclin Gl (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Res 1995; 55: 5493-5498.
168. Yang ZY et al. The P21 JWaf 1 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nature Med 1995; 1: 10521056.
169. Jin X et al. Cell cycle arrest and inhibition of tumor cell proliferation by the pl6 INK4 gene mediated by adenovirus vector. Cancer Res 1995; 55: 3250-3253.
170. Sandig V et al. Adenovirally transfected pl6 INK4JCDKN2 and p53 genes co-operate to induce apoptotic tumor cell death. Nature Med 1997; 3: 313-319.
171. Clarke MF et al. A recombinant bclXS adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. Proc Natl Acad Sci USA 1995; 92: 11024-11028.
172. Dole MG et al. BclXS enhances adenoviral vector-induced apoptosis in neuroblastoma cells. Cancer Res 1996; 56: 57345740.
173. Ealovega M W et al. BclXS gene therapy induces apoptosis of human mammary tumors in nude mice. Cancer Res 1996; 56: 1965-1969.
174. Sumantran VN et al. Overexpression of bclX S sensitizes MCF7 cells to chemotherapy-induced apoptosis. Cancer Res 1995; 55: 2507-2510.
175. Sakakura C et al. Overexpression of bax sensitizes human breast cancer MCF7 cells to radiation-induced apoptosis. Int ] Cancer 1996; 67: 101-105.
176. Strobel T, Swanson L, Korsmeyer S, Cannistra SA. Bax enhances paclitaxel-induced apoptosis through a P53-independent pathway. Proc Natl Acad Sci USA 1996; 93: 1409414099.
177. Coll J-L et al. Antitumor activity of Bax and P53 naked gene transfer in lung cancer. In vitro and in vivo analysis. Hum Gene Ther (submitted).
178. Yu JS et al. Retroviral delivery and tetracycline-dependent expression of IL-lb-converting enzyme (ICE) in a rat glioma model provides controlled induction of apoptotic death in tumor cells. Cancer Res 1996; 56: 5423-5427.
179. Weller M et al. FasJAPOl gene transfer for human malignant glioma. Cancer Res 1995; 55: 2936-2944.
180. Asher AL et al. Murine tumor cells transduced with the gene for TNF a. J Imimmol 1991; 146: 3227-3234.
181. Hwu P et al. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with TNFa cDNA for the gene therapy of cancer in humans. J Imnninol 1993; 150: 4104-4115.
182. Tos AG, Cignetti A, Rovera G, Foa R. Retroviral vectormediated transfer of the TNFa gene into human cancer cells restores an apoptotic cell death program and induces a bystander killing effect. Blood 1996; 87: 2486-2495.
183. Feng M et al. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 1995; 55: 2024-2028.
184. Georges RN et al. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense liras construct. Cancer Res 1993; 53: 1743-1746.
185. Mukhopadhyay T, Tainski M, Cavender AC, Roth JA. Specific inhibition of K ras expression and tumorigenicity of lung cancer cells by antisense DNA. Cancer Res 1991; 51: 1744-1748.
186. Zhang Y et al. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 1993; 4: 451-160.
187. Kasid U et al. Effect of antisense c-rafl on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science 1989; 243: 1354-1356.
188. Led with B et al. Antisense fos RNA causes partial reversion of the transformed phenotypes induced by the c Ha ras oncogene. Mol Cell Biol 1990; 10: 1545-1555.
189. Sklar MD et al. Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH3T3 cells. Mol Cell Biol 1991; 11: 36993710.
190. Wang HG et al. Apotosis regulation by interaction of Bcl2 protein and Raf 1 kinase. Oncogene 1994; 9: 2751-2756.
191. Nooter K et al. Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line. Br ] Cancer 1995; 71: 556-561. :
192. Bedi A et al. Inhibition of apoptosis by Bcr-Abl in chronic myeloid leukemia. Blood 1994; 83: 2038-2044.
193. McGahon A et al. Bcr-abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 5: 1179-1187.
194. Smetsers TFCM et al. Antisense bcr-abl oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia 1994; 8: 129-140.
195. Skorski T et al. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. Blood 1996; 88: 1005-1012.
196. Skorski T et al. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr-abl antisense oligodeoxynucleotides. J Natl Cancer List 1997; 89: 124-133.
197. Keith FJ, Bradbury DA, Zhu YM; Russell NH. Inhibition of bcl2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukenua 1995; 9: 131-138.
198. Kitada S et al. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl2 gene expression. Antisense Res Dev 1994; 4: 71-79.
199. Reed JC et al. Antisense mediated inhibition of bcl2 proto-oncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res 1990; 50: 6565-6570.
200. Reed JC et al. Bcl2 mediated tumorigenicity of a human T lymphoyd cell line: synergy with myc and inhibition by bcl2 antisense. Proc Natl Acad Sci USA 1990; 87: 3660-3664.
201. Cotter FE ct al. Antisense oligonucleotides suppress B cell lymphoma growth in a SCID-hu mouse model. Oncogene 1994; 9: 3049-3055.
202. VVebb A et al. Bcl2 antisense therapy in patients with nonHodgkin lymphoma. Lancet 1997; 349: 1137-1141.
203. Kondo S et al. Bcl2 gene enables rescue from in vitro myelosuppression (bone marrow cell death) induced by chemotherapy. Br ] Cancer 1994; 70: 421-426.
204. Dole MG et al. BclXL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 1995; 55: 2576-2582.
205. Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of bclX L can confer a multidrug resistance phenotype. Blood 1995; 86: 1903-1910.
206. Debbas M, White E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dm 1993; 7: 546-554.
207. Löwe SW, Ruley HE. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 El A and accompanies apoptosis. Genes Dev 1993; 7: 535-545.
208. Teodoro JC, Shore GC, Branton PE. Adenovirus E1A proteins induce apoptosis by both p53-dependent and p53-independent mechanisms. Oncogene 1995; 11: 467-474.
209. Boyd JM et al. Adenovirus El B 19 kDa and Bcl2 proteins interact with a common set of cellular proteins. Cell 1994; 79: 341-351.
210. Han J el al. The E1B protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev 1996; 10: 461-477.
211. Rao L et al. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19 kDa and Bcl2 proteins. Proc Natl Acad Sci USA 1992; 89: 7742-7746.
212. White E, Cipriani R, Sabbatini P, Denton A. Adenovirus E1B 19 kDa protein overcomes the cytotoxicity of El A proteins. J Virol 1991; 65: 2968-2978.
213. Brough DE et al. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions El and E4. J Viral 1996; 70: 6497-6501.
214. Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
215. Feigner PL et al. Nomenclature for synthetic gene delivery systems. Hum Gene Ther 1997; 8: 511-512.
216. Ebert O et ni. Lymphocyte apoptosis: induction by gene transfer techniques. Gene Therapy 1997; 4: 296-302.
217. Shier VVT. Why study mechanisms of cell death? Mcth Achiev Exp Pallid 1988; 13: 1-17.